Dr. Katherine Bowdish Announced as new President and CEO
August 20, 2020
NATICK, MA – August 12, 2020 – PIC Therapeutics (“PIC”), a biotechnology company focused on transforming the treatment of cancer through the selective modulation of oncogene translation, today announced the appointment of Katherine Bowdish, Ph.D., as its President and Chief Executive Officer. Dr. Bowdish will also join the Board of Directors of PIC.
Dr. Bowdish brings more than 20 years of biopharmaceutical business and scientific leadership to PIC Therapeutics. Kathy was most recently at Sanofi, where she launched and led Sanofi Sunrise, a venture investment and partnering vehicle to accelerate early stage pioneering science for patients benefit through unique relationships with leading entrepreneurs, and more recently served as Vice President and Head of R&D Strategy. Prior to her leadership roles at Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies. Kathy’s positions include President & CSO, Permeon Biologics; Co-founder, President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals; and Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion.
Kathy has served on the Boards of Directors of MyoKardia, Warp Drive Bio, Portal Instruments, Thermalin, Permeon Biologics, Anaphore and Prolifaron, and most recently served as an Observer on the DiCE Molecules Board. Kathy received her Ph.D. in molecular genetics from Columbia University College of Physicians and Surgeons, and her B.Sc. degree from the College of William and Mary.
“We are thrilled to have Dr. Bowdish joining PIC as CEO. Her proven strategic leadership and investment experience will be vital to realizing the full potential of PIC’s scientific platform as it advances PIC’s drug candidates toward human clinical studies,” stated PIC Therapeutics’ Executive Chairman, Alan Walts. “Kathy additionally has deep experience in developing the kind of innovative strategic partnerships that will be a critical part of PIC’s success.”
“The promise of addressing broad-based genomic anomalies in cancer through modulating translation of oncogene RNA provides a unique opportunity to create impactful new therapies for patients with cancer,” said Dr. Bowdish. “I am excited to be joining the PIC Therapeutics team and look forward to leading the company as we advance drug candidates through remaining preclinical and translational studies, and into the clinic for patients in need.”
About PIC Therapeutics
PIC Therapeutics is a Natick, MA-based biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation. PIC’s therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. PIC Therapeutics' selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics that address drug resistance and tumor heterogeneity, issues that plague many existing treatments. For more information visit .
PIC is guided by a dedication to improving cancer patient outcomes and to realizing the potential of our technology to their benefit.